上皮性卵巢癌的腹腔热灌注化疗:一项荟萃分析
该荟萃分析纳入15项研究(10项病例对照研究和5项随机对照试验),评估细胞减灭术时行腹腔热灌注化疗(HIPEC)对上皮性卵巢癌的疗效。按末次全身化疗至手术间隔分组:近期暴露组(<6个月)HIPEC改善无进展生存(HR 0.585)和总生存(HR 0.519);非近期暴露组(≥6个月)则无显著影响。结论认为HIPEC的价值似乎取决于末次全身化疗暴露的时间。
要点
- 近期化疗暴露组(<6个月)HIPEC改善无进展生存(HR 0.585,95%CI 0.422-0.811)和总生存(HR 0.519,95%CI 0.346-0.777)。
- 非近期化疗暴露组(≥6个月)HIPEC对无进展生存(HR 1.037)和总生存(HR 0.932)无显著影响。
- 作者认为HIPEC在细胞减灭术中的价值似乎取决于末次全身化疗暴露的时间,未来试验有待明确其作用。
核心结论
- 该荟萃分析表明,上皮性卵巢癌细胞减灭术时行HIPEC的价值似乎取决于末次全身化疗暴露的时间。
- 未来试验有待明确HIPEC在上皮性卵巢癌中的作用。
研究设计与样本
- 系统检索MEDLINE、EMBASE和Cochrane Library数据库,从上皮性卵巢癌HIPEC的首篇报告至2022年4月3日。
- 共纳入15项研究,包括10项病例对照研究和5项随机对照试验(RCT)。
- 根据末次全身化疗至细胞减灭术±HIPEC的时间间隔,将研究和患者队列分为近期化疗暴露组(<6个月,n=9项研究/患者队列)和非近期化疗暴露组(≥6个月,n=8项研究/患者队列)。
- 该荟萃分析在PROSPERO注册(CRD42021265810)。
主要发现
- 近期化疗暴露组中,HIPEC与无进展生存改善相关(HR 0.585;95%CI 0.422-0.811)。
- 近期化疗暴露组中,HIPEC与总生存改善相关(HR 0.519;95%CI 0.346-0.777)。
- 非近期化疗暴露组中,HIPEC未能显著影响无进展生存(HR 1.037;95%CI 0.684-1.571)。
- 非近期化疗暴露组中,HIPEC未能显著影响总生存(HR 0.932;95%CI 0.607-1.430)。
- 后续敏感性分析观察到一致的结果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The value of hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of cytoreductive surgery (CRS) for epithelial ovarian cancer (EOC) is controversial and its use remains experimental in most national and international guidelines. We wished to systematically evaluate all available evidence. METHODS: A comprehensive review of data from MEDLINE, EMBASE, and Cochrane Library databases was conducted from the first report on HIPEC in EOC till April 3, 2022. Progression-free survival (PFS) and overall survival (OS) were compared between the HIPEC and control groups. This meta-analysis was registered with PROSPERO (CRD42021265810). RESULTS: Fifteen studies (10 case-control studies and 5 randomized controlled trials [RCTs]) were included in the present meta-analysis. Based on the time interval between the last systemic chemotherapy exposure and timing of CRS +/- HIPEC, all studies and patients' cohorts we classified into recent (<6 months; n = 9 studies/patients cohorts) and non-recent (≥6 months, n = 8 studies/patients cohorts) chemotherapy exposure groups. In the recent chemotherapy exposure group, HIPEC was associated with improvement of both PFS (HR, 0.585; 95% CI, 0.422-0.811) and OS (HR, 0.519; 95% CI, 0.346-0.777). On the contrary, in the non-recent chemotherapy exposure group, HIPEC failed to significantly affect PFS (HR, 1.037; 95% CI, 0.684-1.571) or OS (HR, 0.932; 95% CI, 0.607-1.430). Consistent results were observed in subsequent sensitivity analyses. CONCLUSION: Our present meta-analysis demonstrates that the value of HIPEC at CRS for EOC appears to depend on the timing of the last systemic chemotherapy exposure. Future trials are awaited to define the role of HIPEC in EOC.
引用
- Kim SI, Kim JH, Lee S, et al. Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis. Gynecol Oncol. 2022. PMID: 36273925. doi:10.1016/j.ygyno.2022.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。